A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
A phase 2 trial of Glecirasib in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib is a phase 2 interventional study registered as NCT07164170 by Abbisko Therapeutics Co, Ltd, with 86 participants planned, started 2025-09-22 and due to reach its primary completion in 2028-12-30. Interventions recorded: ABSK043 in combination with Glecirasib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Shares Glecirasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
- TrialA Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Shares Glecirasib, Non-small-cell lung cancer.
- TrialA Phase 2 Clinical Study of ABSK061 and ABSK043
Shares Abbisko Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Shares Glecirasib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Shares Glecirasib, Non-small-cell lung cancer.
- CompanyMerck KGaA (EMD Serono)